Myelodysplastic Syndromes


Molecular and functional characterisation of bone marrow function in normal subjects, myelodysplastic syndromes (MDS) and secondary disorders of haematopoiesis

AML 17

The AML 17 trial has two distinct parts:

i.For patients with acute myeloid leukaemia (AML), (other than acute promyelocytic leukaemia) and High Risk Myelodysplasia, as defined by the WHO Classification (2001) (Appendix A, protocol).

ii.For adults with acute promyelocytic leukaemia (APL).



Red blood cell transfusion thresholds and QoL in myelodysplastic syndromes: a pilot, feasibility study